Bluejay Diagnostics prices USD 8.5 million at-the-market private placement of shares, warrants

Bluejay Diagnostics, Inc.

BJDX

0.00

Bluejay Diagnostics priced an at-the-market private placement for 3,655,917 common shares or pre-funded warrants at USD 2.33 each.
Deal includes Series G warrants, short-term Series H warrants for up to 3,655,917 shares each; exercise price USD 2.08.
Expected gross proceeds USD 8.5 million; warrant exercise could add about USD 15.1 million in gross proceeds.
Closing targeted for June 3, 2026; H.C. Wainwright serving as exclusive placement agent.
Proceeds earmarked for FDA approval work, related clinical studies, R&D, working capital; cash runway projected into Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606021219PRIMZONEFULLFEED9730620) on June 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.